NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Jasper Therapeutics, Inc. (JSPR) Stock Analysis

Jasper Therapeutics, Inc. (JSPR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

JSPR

$0.50

+$0.00 (+0.88%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JSPR with… →

JSPR Key Statistics

As of Oct 21, 2026
Trading
Open
$0.52
Previous Close
$0.50
Day's Range
0.50–0.54
52-Week Range
0.32–2.57
Volume
358.78K
Valuation
Market Cap
$16.78M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.04
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$75.80M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
33.27M
1-Year Return
−80.15%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
510.11K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, JSPR closed at $0.50, −80.15% over 1 year.

Jasper Therapeutics, Inc. (JSPR) has a market capitalization of $16.78M.

In fiscal 2025, JSPR reported revenue of $0.00.

JSPR Stock Return by Calendar Year

Jasper Therapeutics, Inc. (JSPR) return since Jan 2020: what $10,000 became

1 year
$10,000 $1,985
−80.15%
5 years
$10,000 $38
−99.62%
Since Jan 2020
$10,000 $51
−99.49%

If you had invested $10,000 in Jasper Therapeutics, Inc. (JSPR) at the close on January 10, 2020, the earliest close on record here, it would have been worth $51 at the close on October 21, 2026: −99.49% in total, −54.05% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−72.44%
2025−91.44%
2024+170.98%
2023+63.35%
2022−93.85%
2021−21.58%
2020+1.93%

As of October 21, 2026.

JSPR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$75.80M—
2024$0.00−$71.27M—
2023$0.00−$64.47M—
2022$0.00−$37.69M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$83.88M−$75.80M—
2024$0.00—−$76.24M−$71.27M—
2023$0.00—−$68.86M−$64.47M—
2022$0.00—−$51.20M−$37.69M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Jasper Therapeutics, Inc. (JSPR) at $16.78M. It is classified in the Biotechnology industry, within the Healthcare sector.

The 52-week range on file runs from $0.32 to $2.57. The most recent close on file for JSPR is $0.50, dated October 21, 2026. That is $0.00 (+0.88%) against the previous close. The latest close sits 60.1% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $75.80M. Earnings per share on a trailing basis come to −1.04.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Daily returns over the trailing 6 years annualize to a volatility of 216.9%. Over the trailing twelve months the total return is −80.15%. Measured over 5 years, that is −67.18% a year compounded.

Growth & Income

No dividend is on file for JSPR.

Across the complete calendar years on file, 2024 returned +170.98% and 2022 returned −93.85%. Of the 6 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is −72.44% year to date.

Peer Comparison

Jasper Therapeutics, Inc. (JSPR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Jasper Therapeutics, Inc. JSPR $16.78M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Jasper Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.

Visit website →